ArticleNeoplasia (New York, N.Y.)2009
The angiopoietin/Tie2 axis mediates malignant pleural effusion formation.
Article in Neoplasia (New York, N.Y.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Assessment of Angiogenic Properties of Malignant Pleural Effusion (MPE) Fluid.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Analysis of tumor markers in pleural effusion and serum to verify the correlations between serum tumor markers and tumor size, TNM stage of lung adenocarcinoma.Cancer medicine · 2020Article
- A Case of Massive Cerebral Arterial Air Embolism Induced by Artificial Pneumothorax and Its Analysis.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2019Article
- Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications.Oncotarget · 2018Article
- Autophagy regulates vinorelbine sensitivity due to continued Keap1-mediated ROS generation in lung adenocarcinoma cells.Cell death discovery · 2018Article
- Angiopoietins as biomarkers of disease severity and bacterial burden in pulmonary tuberculosis.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2017Article
- Malignant pleural effusion: from bench to bedside.European respiratory review : an official journal of the European Respiratory Society · 2016Review
- Switching off malignant pleural effusion formation-fantasy or future?Journal of thoracic disease · 2015Review
- Effect of Endostar combined with angiopoietin-2 inhibitor on malignant pleural effusion in mice.Medical oncology (Northwood, London, England) · 2015Article
- Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion.Oncogene · 2013Article
- Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion.PloS one · 2013Article
- Article
- Malignant pleural effusion: tumor-host interactions unleashed.American journal of respiratory and critical care medicine · 2012Review
- The interconnectedness of cancer cell signaling.Neoplasia (New York, N.Y.) · 2011Article
- Dinosaurs and ancient civilizations: reflections on the treatment of cancer.Neoplasia (New York, N.Y.) · 2010Article
- The War on Cancer rages on.Neoplasia (New York, N.Y.) · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAngiopoietins and their receptor, Tie2, participate in angiogenesis, regulation of vascular permeability, and inflammation, all central to the pathogenesis of malignant pleural effusions (MPEs). In the present study, we aimed to examine the role of the angiopoietin/Tie2 axis in MPE pathogenesis. EXPERIMENTAL
designMPE was induced by intrapleural injection of murine adenocarcinoma cells in C57BL/6 mice. Animals were given twice-weekly intraperitoneal injections of 40 mg/kg MuTekdeltaFc or vehicle. MuTekdeltaFc is a soluble Tie2 (sTie2) receptor that binds murine angiopoietins thereby disrupting their interaction with Tie2 receptors expressed on tissues. Animals were killed on day 14.
resultsAngiopoietin/Tie2 axis blockade significantly reduced pleural fluid volume and pleural tumor foci. The mean +/- SEM pleural fluid volumes were 617 +/- 48 microl and 316 +/- 62 microl for the control and treated groups, respectively (P = .001), whereas the mean +/- SEM tumor foci were 7.3 +/- 1.0 and 3.0 +/- 0.52 for the control and treated groups, respectively (P = .001). In addition, tumor-associated cachexia, tumor angiogenesis, pleural vascular permeability, recruitment of inflammatory cells to the pleural cavity, and local elaboration of vascular endothelial growth factor and interleukin 6 were also downregulated, and tumor cell apoptosis was induced in animals treated with the inhibitor.
conclusionsOur results indicate that the angiopoietin/Tie2 axis is an important component of MPE pathogenesis. Further studies are required to determine whether therapeutic interventions targeting this pathway could be beneficial for patients with MPE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.